In this study we investigated the contribution of sphingosine kinase 1 (SphK1) overexpression to cetuximab resistance, both intrinsic or acquired, in colorectal cancer. In preclinical models with intrinsic or acquired resistance, SphK1 inhibition through different approaches partially restored sensitivity to cetuximab. The effect of fingolimod, a clinically available antagonist of sphingosine-1-phosphate (S1P) receptor, in cetuximab resistant colorectal cancer models was also demonstrated, both in vitro and in vivo. Moreover, we observed a correlation between SphK1 expression and cetuximab response in metastatic colorectal cancer patients. Therefore, our data support cetuximab plus fingolimod as a novel therapeutic combination to be tested in the clinical setting for cetuximab resistant colorectal cancer patients. 
INTRODUCTION
In the last years, cetuximab and panitumumab, two monoclonal antibodies (mAbs) targeting the Epidermal Growth Factor Receptor (EGFR), have proven to be effective in combination with chemotherapy or as single agents for treatment of metastatic colorectal cancer (1) . However, as is common in cancer therapy, intrinsic or acquired resistance to anti-EGFR drugs by different mechanisms have been widely observed (2) . Molecular alterations such as mutations in genes codifying for EGFR-dependent signal transducers (K-Ras, B-Raf, PI3K, PTEN) have been related to primary refractoriness to cetuximab in colorectal cancer. Other mechanisms, such as alternative signalling by different TKRs or induction of angiogenesis by tumor-derived factors, could be also involved, particularly in the onset of resistance over prolonged treatment (3) . Therefore, there is an urgent need to identify novel predictive markers of response to cetuximab as well as to develop novel therapeutic strategies for colorectal cancer patients with intrinsic or acquired resistance to this agent.
Sphingolipids are a family of molecules enriched in lipid rafts that contribute to their unique biochemical properties. Sphingolipid metabolites including ceramide, sphingosine, ceramide-1-phosphate (C1P) and sphingosine-1-phosphate (S1P) have emerged as bioactive signalling molecules, with ceramide and sphingoid bases serving as activators of cell death pathways whereas S1P and C1P primarily exert mitogenic effects (4) . Altered regulation of the S1P/ceramide ratio can lead to an imbalance in the 'sphingolipid rheostat' through which these sphingolipid metabolites influence cell fate and tissue homeostasis. The balance of these molecules is critically regulated by sphingosine kinase (SphK), which converts sphingosine to S1P by phosphorylation (5) . Two SphK isoforms have been cloned and characterized to date. SphK1, activated by a variety of growth factors, cytokines and mitogens, is up-regulated in many cancers, often correlating with higher clinical grade and resistance to standard therapy (6; 7) . Consistently, interference with SphK1 activity by dominant-negative mutants or competitive inhibitors such as N,N-dimethyl-sphingosine (DMS), as well as inhibition of S1P by mAbs or S1P receptors antagonists such as fingolimod (FTY720, Novartis), blocks tumorigenesis and tumor angiogenesis in cancer models (8) . Moreover, recent studies demonstrated that alterations of ceramide/S1P rheostat may be involved in the regulation of resistance to both chemotherapeutics and targeted agents (9) (10) (11) (12) (13) (14) .
Based on this evidence, and since several reports showed cross-talks between SphK1 and EGFR-dependent signalling pathways (15; 16), we analyzed the contribution of sphingolipid rheostat alterations to cetuximab resistance in human colorectal cancer models. Moreover, we investigated the combination of cetuximab and fingolimod as a therapeutic strategy potentially effective in colorectal cancers resistant to cetuximab.
Research. Sphingosine kinase assay. SphK1 activity was measured by using Sphingosine Kinase Activity Assay Kit (Echelon Biosciences, Salt Lake City, UT, USA) (18; 19) .
Quantification of S1P. Quantification of S1P from cell protein extracts, tumor lysates or mice sera by ELISA assay was performed using a validated S1P Assay Kit (Echelon Biosciences) (20; 21) .
Hairpin siRNA construct for Sphk1. Endogenous Sphk1 expression was down-regulated with sequence-specific pSilencer-siSphK1 851 (Clone1) and 1118 (Clone2), as previously described (22) , as well as with Silencer® Select Validated siRNA s16957 and s16959. A nonsense sequence was used as a negative control. tumors were detected and groups of 10 mice were randomized to receive: Cetuximab 10 mg/kg intraperitoneally (i.p.) three times a week for 3 weeks, fingolimod 2.5 mg/kg i.p. three times a week for 3 weeks, or the combination. Tumor volume (cm 3 ) was measured using the formula π/6 x larger diameter x (smaller diameter) 2 as previously reported (23) .
Transfection of human
Morphological and immunohistochemical analysis of mouse and human tumor samples.
Research. The morphological evaluation of necrosis-grade was done on hematoxilin/eosin stained 5-μm slides were detected only in HCT116 cells (Fig.1A) , as previously reported (27) . Consistently, SphK1 enzymatic activity (Fig.1B) , as well as levels of S1P measured in cell lysates (Fig.1C) , were higher in cells with intrinsic or acquired resistance to cetuximab. Lower SphK1 activity and S1P levels were detected in HCT116 cells (Fig.1B, C) .
We then tested sensitivity of colorectal cancer cell lines to DMS, a potent competitive inhibitor of SphK1. Consistently with the previous finding, higher doses of DMS were needed to achieve complete enzyme saturation and survival inhibition in resistant cells (Fig.1D) . Moreover, the proapoptotic molecule ceramide, a precursor of sphingosine, induced apoptosis less efficiently in resistant than in sensitive cells, consistently with the idea that increased SphK1 levels mediate S1P synthesis by ceramide in resistant cells. Also in this case, the only exception was the HCT116 cell line (Fig.1E) . As a confirm of SphK1 overactivity, SphK1 inhibition by DMS potentiated the effects of ceramide in resistant GEO-CR and SW480 cells, with a two-fold increase in apoptosis after combined treatment compared to ceramide alone (Fig.1F) .
SphK1 inhibition partially restores sensitivity to cetuximab in resistant colorectal cancer cell lines.
Based on the overexpression of SphK1 in resistant cells, we investigated the involvement of this kinase in cetuximab resistance by performing combined treatment of GEO-CR, SW480, LS174T, HT29 and LoVo cells with DMS and cetuximab. DMS was able to significantly restore sensitivity to cetuximab in resistant cells (Supplementary Fig.S2A ). Most interestingly, while neither DMS or cetuximab were able to produce significant apoptosis induction in resistant cells, the combination of these agents was effective; this result was comparable to that obtained with cetuximab alone in sensitive cells (Supplementary Fig.S2B ). These data demonstrate that SphK1 blockade may restore cetuximab activity in resistant cancer cells.
We also studied the effects of modulating SphK1 expression in resistant cancer cell lines.
SphK1 gene silencing via siRNA in GEO-CR, SW480, HT29 and LoVo SphK1-overexpressing resistant cells caused a marked decrease in SphK1 protein expression ( Fig.2A and Supplementary   Fig.S3A ). SphK1 silencing was not achieved in LS174T cells due to low transfection efficiency (data not shown). In all the tested cells, treatment with SphK1 siRNA led to reduced Akt phosphorylation/activation ( Fig.2A and Supplementary Fig.S3A ), SphK1 enyzme activity (Fig.2B) and S1P production ( Supplementary Fig.S3B ). Moreover, as shown in figure 2C , SphK1 silencing increased sensitivity to cetuximab-induced apoptosis in resistant cells. Conversely, SphK1 overexpression in GEO and SW48 sensitive cells through a full-length expression vector increased SphK1 and SphK1 phospho-Ser225 protein levels ( Fig.2D and Supplementary Fig. S3C) (Fig.2E ) and S1P production ( Supplementary Fig.S3D ). As a further confirm, SphK1 overexpression significantly prevented cell death in response to cetuximab in GEO/SphK1 and SW48/SphK1 cells compared to controls. Moreover, in these cells, SphK1 inhibition by DMS significantly restored sensitivity to cetuximab-induced apoptosis (Fig.2F) .
The S1PR antagonist fingolimod restores sensitivity to cetuximab in colorectal cancer cell lines.
To further assess the role of SphK1 in cetuximab resistance, we used fingolimod (FTY720), a S1PR antagonist that could also act as a SphK1 inhibitor. This drug is currently available for the treatment of multiple sclerosis (28) and has showed anticancer properties in different models of human cancers (8; 29; 30) . This agent moderately inhibits survival of all cell lines, with an IC 50 ≥ 5µM (data not shown). Then we evaluated fingolimod capability to restore cetuximab activity in resistant cells. As shown in figures 3A and B, fingolimod significantly potentiated survival inhibition and apoptosis induction by cetuximab in GEO-CR, SW480, HT29 and Lovo cells. Therefore, we analyzed the effect of the combination cetuximab plus fingolimod on SphK1 enzymatic activity and S1P production. In all cell lines, cetuximab did not affect SphK1 activity and S1P levels, while fingolimod reduced them. Statistically significant reductions of SphK1 enzymatic activity and S1P levels were detected with the combined treatment (Fig.3C, D) . Finally, we investigated the activation of EGFR signal transducers mainly involved in the onset of resistance to cetuximab. In four different resistant cells, cetuximab was ineffective in inhibiting Akt and/or MAPK phosphorylation. Fingolimod produced a variable effect, while the combined treatment strongly interfered with both Akt and MAPK phosphorylation/activation in all cell lines (Fig.3E) .
Fingolimod restores sensitivity to cetuximab in colorectal cancer xenografts in nude mice.
In order to confirm the antitumor effect of the combination fingolimod plus cetuximab also in in vivo models of cetuximab resistance, we xenografted GEO-CR cells in nude mice.
Research. table S1 ).
Western blot analysis on tumor samples from mice sacrificed on day 25 demonstrated that fingolimod not only inhibits phosphorylation of SphK1 on Ser225, but efficiently interferes also with EGFR-dependent signal transduction, by reducing EGFR, Akt and MAPK activated forms.
The combination was more efficient than fingolimod alone, producing an almost total suppression of EGFR and Akt phosphorylation/activation. No alterations in expression of SphK1 and S1PR1
were detected (Fig. 4C) . ELISA assays on tumor lysates and mice sera revealed that fingolimod significantly reduces S1P production by tumor cells, but the combined treatment was much more effective (Fig. 4D) . fingolimod as single agents. We also investigated the long-term induction of apoptosis by performing immunohistochemical analysis of annexin V on tumor samples from mice sacrificed on day 25: a relevant staining was found only in tumors treated with both cetuximab and fingolimod (Fig. 5A) . Moreover, the necrosis-grade was low in the control, intermediate in the cetuximab-or fingolimod-treated tumors, and high in the combination-treated tumors (Fig. 5B ).
SphK1 expression is related to cetuximab response in colorectal cancer patients.
Based on this body of data, and since alterations of ceramide/S1P rheostat mediated by Fig.S5A ). This polyclonal Ab was validated for specificity and reproducibility by using a previously described algorithm (25) . Briefly, it showed a band of the expected molecular weight in Western blot analysis, produced a specific and localized staining when titered on tissue microarray (TMA) containing control tissues, and was reproducible between different runs and lots ( Supplementary Fig. S5B, C) . 
DISCUSSION
Although a number of molecular alterations have been identified as responsible for resistance to EGFR inhibitors available in clinical practice, such as cetuximab for colorectal cancer, each of these mechanisms only partially justifies the lack of response in patients. Therefore, the search for further determinants of resistance may help to better select patients potentially responsive to cetuximab and to develop novel therapeutic strategies for resistant cancers (1; 2).
Based on the evidence that alterations of ceramide/S1P rheostat may be involved in resistance to biological agents (9; 13; 14) and since some reports showed cross-talks between SphK1 and EGFR-dependent pathways (15; 16; 31), we investigated the role of SphK1 in the onset of resistance to cetuximab in colorectal cancers. To this aim, we analyzed SphK1 expression and activation in preclinical models of colorectal cancer, both sensitive or with intrinsic/acquired resistance to cetuximab. We found that SphK1 is overexpressed and overactivated in colorectal cancer cell lines resistant to cetuximab. In fact, high expression of the activated form of SphK1, produced by MAPK-mediated phosphorylation on Ser225 (32), as well as high levels of enzyme activity and S1P production, were detected in resistant cells. Then, we investigated whether SphK1 inhibition could restore cetuximab sensitivity in resistant cancer cells. To this aim, we used different approaches, including DMS, a potent, even if not specific (33) , competitive inhibitor of SphK1, the S1PRs antagonist fingolimod, and siRNAs specific for SphK1. By combining each of these tools with cetuximab on resistant cells, we demonstrated that SphK1 inhibition was able to partially restore cetuximab capability to affect cell survival, apoptosis and EGFR-dependent signal transduction. We particularly focused on signal transducers classically involved in the development of resistance to EGFR inhibitors, such as the PI3K/Akt/mTOR and the Ras/MEK/MAPK pathways:
The combination of cetuximab with fingolimod produced a strong suppression of Akt and MAPK phosphorylation/activation in resistant cells. These results are consistent with other studies demonstrating the capability of S1P to induce cell proliferation and survival through activation of 
the Akt pathway (34) (35) (36) . Most importantly, the re-sensitization to cetuximab induced by SphK1 inhibition was observed in different models of resistance: SW480, HT29 and LoVo cells, whose intrinsic resistance to cetuximab is related to K-Ras or B-Raf mutations and consequent overactivation of the Ras/MAPK pathway, and GEO-CR cells, whose acquired resistance is due to PI3K/Akt overactivation (17).
It has been described that S1P produced by SphK1 may function as a second messenger inside the cell or may be secreted in order to bind to S1PRs on the cell surface. This signalling, involved in several human diseases including cancer, is defined as "inside-out" S1P signalling (37; 38) . Therefore, the re-sensitization to cetuximab that we observed in our cell models may depend on cross-talks of EGFR pathway with both intracellular S1P and/or extracellular S1P/S1PRs signalling pathways. By comparing the effects of SphK1 and S1PRs inhibitors we attempted to explain this point and discriminate between intracellular and extracellular effects of S1P. Fingolimod has been initially defined as a S1PRs antagonist: Its phosphorylated form, produced by SphK2, binds to S1PRs and elicits their polyubiquitination, endocytosis and degradation (39) . In this study, we observed no alteration in S1PR1 protein expression after treatment of GEO-CR xenografts with fingolimod. This result seems to rule out that the effect of fingolimod depends on its antagonistic activity on S1PRs. However, it has been described that fingolimod can act also as a SphK1 inhibitor (29) . Therefore, the re-sensitization to cetuximab in our cell models may depend on cross-talks of EGFR pathway with intracellular S1P signalling rather than with extracellular S1P/S1PRs signalling pathways. Further investigations are needed to clarify this point.
Since several preclinical studies reported the activity of fingolimod in human cancer models As a further confirm of our preclinical data, we examined SphK1 expression in tumor specimens from colorectal cancer patients. To date, SphK1 overexpression has been described in colorectal cancers compared to corresponding normal tissues (40), but we reported for the first time an interesting correlation between SphK1 expression and poor response to cetuximab therapy. This result should be interpreted with caution due to the limited number of patients included in the analysis and it could be used to design dedicated, prospective clinical trials to explore the potential role of SphK1 as a biological marker of resistance to cetuximab.
Taken together, we demonstrate for the first time that SphK1 inhibition is effective in restoring cetuximab antitumor activity in colorectal cancers resistant to this agent. Moreover, since fingolimod is a clinically available drug (28), the results of the present study suggest cetuximab plus fingolimod as a novel therapeutic strategy to be tested in the clinical setting for colorectal cancer patients with resistance to cetuximab. Quantification of S1P (µM) on tumor lysates and mice sera by ELISA assays. **, 2-sided P < 0.05 and *, 2-sided P < 0.005 versus control. Data represent the mean (±SD) of three independent experiments, each performed in triplicate, and are presented relative to control. Bars, SDs. 
